Is infliximab a plausible alternative for neurologic complications of Behçet disease?
We observed a significant beneficial effect of infliximab in neuro-Behçet syndrome.
In early obese Type 2 diabetic patients, serum ox-LDL levels are influenced by short-term serum glucose variations and lowered with cerivastatin therapy. During cerivastatin treatment, improved flow-mediated endothelium-dependent dilation was associated with decrements in circulating ox-LDL levels and the hyperinsulinaemia-induced urinary albumin excretion was blunted.